Chronic Kidney Disease Treatment Market Updates : is Projected to Surpass USD 47.9 billion by 2032; Report
The chronic kidney disease treatment market size was valued at $32 billion in 2022, and is estimated to reach $47.9 billion by 2032, growing at a CAGR of 4% from 2023 to 2032.
- CAGR: 4%
- Current Market Size: USD 32 Billion
- Fastest Growing Region: APAC
- Largest Market: North America
- Projection Time: 2022-2032
- Base Year: 2022
๐๐๐ช๐ฎ๐๐ฌ๐ญ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐จ๐ฉ๐ฒ ๐จ๐ ๐๐๐ฉ๐จ๐ซ๐ญ-https://www.alliedmarketresearch.com/request-sample/107605
What are drivers of Chronic Kidney Disease Treatment Market ?
The chronic kidney disease (CKD) treatment sector is witnessing substantial expansion, propelled by heightened research and development initiatives aimed at introducing innovative medications and enhancing current pharmaceuticals. Additionally, a rising number of approvals from governmental regulatory authorities are offering lucrative opportunities for the market in managing CKD.
Furthermore, investments in research and development are propelling advancements in drug discovery, formulation, and treatment alternatives for CKD patients. Various stakeholders, including pharmaceutical firms, academic institutions, and research organizations, are actively allocating resources to R&D efforts, with the goal of identifying novel therapeutic targets, developing more potent drugs, and refining existing treatment methodologies. This increased focus on research and development is a response to the growing global prevalence of CKD, highlighting the need for more efficacious and sophisticated treatment options.
Recent Product Approval in Chronic kidney disease treatment market
- In May 2023, AstraZenecaโs Farxiga (dapagliflozin) received approval in the U.S. to reduce the risk of cardiovascular (CV) death, hospitalization for heart failure (hHF) and urgent heart failure (HF) visits in adults with HF. The approval by the Food and Drug Administration (FDA) was based on positive results from the DELIVER Phase III trial.
- In February 2023, AstraZenecaโs Forxiga (dapagliflozin) received approval in the European Union to extend the indication for heart failure (HF) with reduced ejection fraction (HFrEF) to cover patients across the full spectrum of left ventricular ejection fraction (LVEF), including HF with mildly reduced and preserved ejection fraction (HFmrEF, HFpEF).
Recent Acquisition in Chronic kidney disease treatment market
In March 2022, B. Braun SE, one of the worldโs leading medical technology companies acquired Intermedt Medizin & Technik GmbH, a specialist in the preparation of dialysis concentrates. With this acquisition the Intermedt product portfolio will be permanently integrated into B. Braun comprehensive range of products and services for dialysis therapy.
๐๐ง๐ช๐ฎ๐ข๐ซ๐ ๐๐จ๐ฎ๐ซ ๐๐ฏ๐๐ซ๐ฒ ๐๐จ๐ฎ๐๐ญ ๐๐๐ซ๐:
https://www.alliedmarketresearch.com/purchase-enquiry/107605
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the chronic kidney disease treatment market analysis from 2022 to 2032 to identify the prevailing chronic kidney disease treatment market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porterโs five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the chronic kidney disease treatment market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global chronic kidney disease treatment market trends, key players, market segments, application areas, and market growth strategies.
๐๐จ๐ฉ Chronic Kidney Disease Treatment ๐๐จ๐ฆ๐ฉ๐๐ง๐ข๐๐ฌ
- AbbVie Inc.
- Baxter International Inc.
- Fresenius SE and Co. KGaA
- AstraZeneca plc
- Teva Pharmaceutical Industries Ltd.
- B. Braun SE
- F. Hoffmann-La Roche Ltd.
- Becton, Dickinson and Company
- Johnson & Johnson
- Pfizer Inc.
Chronic Kidney Disease Treatment Market Segmentation
| By End User |
|
By Treatment
|
|
By Region
|
|
๐ถ๐๐๐๐ ๐ป๐๐๐๐ ๐๐๐ ๐น๐๐๐๐๐๐ ๐๐ ๐ณ๐๐๐ ๐บ๐๐๐๐๐๐ ๐ซ๐๐๐๐๐-
Wound Management Devices Market https://www.alliedmarketresearch.com/wound-management-devices-market-A06272
Mitral Valve Disease Market https://www.alliedmarketresearch.com/mitral-valve-disease-market-A74388
Editor Details
-
Company:
- The Wire Times
